Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
McKesson
Colorcon
McKinsey

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,425,934


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,425,934 protect, and when does it expire?

Patent 8,425,934 protects BRILINTA and is included in one NDA.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 8,425,934
Title:Pharmaceutical compositions
Abstract: The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s): Banks; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/841,030
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,425,934
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form;

Drugs Protected by US Patent 8,425,934

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca BRILINTA ticagrelor TABLET;ORAL 022433-001 Jul 20, 2011 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,425,934

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 062451 ⤷  Try it Free
Australia 2007288541 ⤷  Try it Free
Australia 2011205164 ⤷  Try it Free
Brazil PI0715712 ⤷  Try it Free
Canada 2659328 ⤷  Try it Free
Chile 2007002421 ⤷  Try it Free
China 101505754 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
Boehringer Ingelheim
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.